Cargando…
Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity
BACKGROUND: Bortezomib (Bz) is a proteasome inhibitor that directly targets antibody-producing plasma cells. We recently reported the first randomized control trial that evaluated the effects of Bz in patients with systemic lupus erythematosus (SLE). In that study, we demonstrated that Bz treatment...
Autores principales: | Ikeda, Tomoko, Fujii, Hiroshi, Nose, Masato, Kamogawa, Yukiko, Shirai, Tsuyoshi, Shirota, Yuko, Ishii, Tomonori, Harigae, Hideo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553803/ https://www.ncbi.nlm.nih.gov/pubmed/28800777 http://dx.doi.org/10.1186/s13075-017-1397-7 |
Ejemplares similares
-
A novel autoantibody against ephrin type B receptor 2 in acute necrotizing encephalopathy
por: Shirai, Tsuyoshi, et al.
Publicado: (2013) -
One after another retinal involvement in lupus
por: Mutoh, Tomoyuki, et al.
Publicado: (2021) -
Nasal Septal Perforation in Propylthiouracil-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
por: Ishii, Yusho, et al.
Publicado: (2018) -
Interferon α Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus
por: Akita, Kanae, et al.
Publicado: (2021) -
The use of tacrolimus for recurrent lupus enteritis: a case report
por: Shirai, Tsuyoshi, et al.
Publicado: (2010)